Identification of Genetic Variants Associated With Triple-Negative Breast Cancer And High-Grade Serous Ovarian Cancer
DOI:
https://doi.org/10.61229/mpj.v2i2.46Keywords:
Câncer de ovário seroso de alto grau, Câncer de Mama Triplo Negativo, DNA livre circulante, Biomarcadores, Artificial intelligence, Biópsia liquídaAbstract
Breast and Ovarian Cancer represents challenging diseases for clinical practice nowadays. While the first one is the most common neoplasm affecting the female population, the second, even with a lower incidence, presents elevated mortality2,3. Both diseases have different subtypes. Triple Negative Breast Cancer (TNBC) is the most complex since it does not have any specific target for treatment4. In the same manner, High-Grade Serous Ovarian Cancer (HGSOC) is the more frequent and complex subtype due to its lack of adequate diagnosis3. Different subtypes also require different treatments. Thus, it becomes clear the need for more effective diagnostic methods and the search for new personalized treatments. Therefore, the importance of searching for possible biomarkers for those diseases stands out5. The present study aims to identify potential predictive or prognostic tumor biomarkers actionable to clinical practice in patients with TNBC and HGSOC. For that, blood samples were collected from 10 patients from the Tumor Biobank Mário Penna Institute (CAAE - 82703418.8.0000.5121). Out of these, six were related to TNBC and four to HGSOC. The samples were processed, and the plasma was separated through the standard laboratory procedures. cell-free DNA (cfDNA) was extracted utilizing Quick-cfDNA Serum & Plasma (Zymo). cfDNA library was prepared utilizing xGen DNA Library Prep MC Kit (IDT) and the hybridization with xGen Hybridization capture of DNA Libraries Kit (IDT), conform manufacture instructions. The quantification and quality of the library were assessed utilizing a Qubit fluorometer and TapeStation System, respectively. The final library displayed the expected cfDNA profile. Libraries were sequenced using the 300-cycle high-output kit on the NextSeq 550 (Illumina). Generated more than 30 million reads for each sample. Mapping analyses to the human reference genome (GRCh38), variant calling, and correlation of findings with patient’s clinical data are ongoing and will provide the genetic profile of our studied cohort. This study is in initial phase. However, it has a great potential to identify new prognostic-biomarkers candidates in TNBC and HGSOC1. Furthermore, this study may contribute to expanding knowledge about the factors that influence prognostic outcomes in these diseases, which may favor the development of more personalized therapies and diagnostics based on liquid biopsy1, allowing treating these conditions more quickly and efficiently.
Downloads
References
Fernández-Lázaro D, García-Villalba R, López-Hernández R, Mielgo-Ayuso J, Córdova A. Liquid biopsy as novel tool in precision medicine: Origins, properties, identification and clinical perspective of cancer’s biomarkers. Diagnostics. 2020;10(4):215. DOI: 10.3390/diagnostics10040215. DOI: https://doi.org/10.3390/diagnostics10040215
Giaquinto AN, Sung H, Miller KD, Kramer JL, Jemal A, Islami F, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524-541. DOI: 10.3322/caac.21583. DOI: https://doi.org/10.3322/caac.21754
Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C. High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints. Int J Mol Sci. 2019;20(4):952. DOI: 10.3390/ijms20040952. DOI: https://doi.org/10.3390/ijms20040952
Orrantia-Borunda E, Aguilar-Romero F, Espinoza-Sánchez NA, Torres-Romero JC. Subtypes of breast cancer. Breast Cancer [Internet]. 2022 [citado 2024 nov 15]; Disponível em: https://www.ncbi.nlm.nih.gov/books/NBK583808/. DOI: https://doi.org/10.36255/exon-publications-breast-cancer-subtypes
Zhang R, Siu MKY, Ngan HYS, Chan KKL. Molecular biomarkers for the early detection of ovarian cancer. Int J Mol Sci. 2022;23(19):12041. DOI: 10.3390/ijms231912041. DOI: https://doi.org/10.3390/ijms231912041
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Mário Penna Journal

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Autores que publicam nesta revista concordam com os seguintes termos:
- Declaro que o presente artigo é original, não tendo sido submetido à publicação em qualquer outro periódico nacional ou internacional, quer seja em parte ou em sua totalidade.
- Declaro, ainda, que uma vez publicado na revista Mário Penna Journal, editada pelo Instituto Mário Penna, o mesmo jamais será submetido por mim ou por qualquer um dos demais co-autores, caso haja, a qualquer outro periódico.
- Por meio deste instrumento, em meu nome e em nome dos demais co-autores, porventura existentes, cedo os direitos autorais do referido artigo ao Instituto Mário Penna e declaro estar ciente de que a não observância deste compromisso submeterá o infrator a sanções e penas previstas na Lei de Proteção de Direitos Autorias (Nº9609, de 19/02/98).

A Revista Mário Penna Journal é licenciada sob uma licença Creative Commons Atribuição-NãoComercial-CompartilhaIgual 4.0 Internacional
